First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer - Csiki, Ildiko; Dong, Aiwen; Tuan, Bertrand Y.; John, Elizabeth; O'Toole, Leslie; Seppa, Judy; Huang, Ningwu; Hawley, Ronald C.; Exon, Chris; Glenn, Jeffrey S.; Klumpp, Klaus (Journal of clinical oncology, 2022)